Key Stats
Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.
Stock Score/grades
The Stock Score/Grades evaluate bankruptcy risk and assess the financial strength and fundamental health of a company
- Altman Z Score -16.04
- Piotroski Score 2.00
- Grade Market Outperform
- Symbol (ALLK)
- Company Allakos Inc.
- Price $1.08
- Changes Percentage (-6.9%)
- Change -$0.08
- Day Low $1.04
- Day High $1.17
- Year High $3.41
Allakos Inc., a clinical stage biopharmaceutical company, develops therapeutics that target immunomodulatory receptors present on immune effector cells in allergy, inflammatory, and proliferative diseases. The company's lead monoclonal antibody is lirentelimab (AK002), which is in a Phase III study for the treatment of eosinophilic gastritis and/or eosinophilic duodenitis; a Phase II/III study for eosinophilic esophagitis; and a Phase II clinical study to atopic dermatitis and chronic spontaneous urticaria. It is also developing lirentelimab (AK002) for the treatment of mast cell gastrointestinal disease, chronic urticaria, severe allergic conjunctivitis, and indolent systemic mastocytosis; and AK006 to treat allergic and inflammatory diseases. The company was incorporated in 2012 and is headquartered in Redwood City, California.
- Last Earnings
- Ex-Dividend for 5/16 Dividend
- Dividend Payable
- Today N/A
- Next Earnings (Estimated) 03/04/2025
- Fiscal Year End N/A
- Average Stock Price Target $109.50
- High Stock Price Target $218.00
- Low Stock Price Target $1.00
- Potential Upside/Downside N/A
- Consensus Rating Sell
- Rating Score (0-4) N/A
- Research Coverage N/A
- EPS (Most Recent Fiscal Year) -$2.46
- Trailing P/E Ratio -0.47
- Forward P/E Ratio -0.47
- P/E Growth -0.47
- Net Income $-185,701,000
Income Statement
Quarterly
Annual
Latest News of ALLK
The Latest News section aggregates recent news posts from various news outlets, offering a comprehensive overview of the most recent developments related to the topic.
-
Can Allakos (NASDAQ:ALLK) Afford To Invest In Growth?
Investors are often attracted to unprofitable companies that show potential for growth, like Salesforce.com. However, these companies carry risks due to cash burn. Allakos' cash burn rate and cash res...
By Yahoo! Finance | 3 months ago
